Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Adverse drug reactions

Increased blood clot risk in first six months of testosterone therapy

Researchers found the risk of venous thromboembolism peaks within the first six months of hormone treatment, but further research is needed to confirm the results.

Blood clot micrograph

Source: Scott Camazine / Alamy Stock Photo

There may be an increased risk of serious blood clots with testosterone treatment, study finds

Testosterone treatment is associated with an increased risk of serious blood clots, according to the results of an observational study of almost 1 million UK men. 

Researchers analysed records from 370 general practices in UK primary care involving 19,215 patients with venous thromboembolism, comprising deep venous thrombosis and pulmonary embolism, and compared them with 909,530 matched controls.

The team found the increased risk of venous thromboembolism peaks within the first six months of taking the hormone before dropping off again.

The researchers split the patients into those who had recently had testosterone treatment but were not taking it currently; those who were currently on testosterone treatment for either more than six months or less than six months; and those who had not had any treatment for two years.

The researchers found a 25% increased risk of venous thromboembolism for those currently on treatment compared with those not taking testosterone.

The highest risk was found in those who were less than six months into treatment, with a 63% increased chance of a clot compared with those who had not used testosterone.

The findings, however, only equate to an extra ten cases of venous thromboembolism per 10,000 person years in men who have just started taking testosterone over the general rate of 15.8 blood clots per 10,000 person years, the researchers said. 

Reporting in The BMJ[1] (online, 30 November 2016), the researchers say the transient nature of the increased risk could explain why previous studies have reported contradictory results.

There has been a striking increase in the prescribing of testosterone in the past decade with a ten-fold increase in the United States. Much of this is for “unclear and questionable indications”, the researchers say, including sexual dysfunction and low energy.

Richard Quinton, a member of the Society for Endocrinology and consultant endocrinologist at Newcastle upon Tyne Hospitals NHS Foundation Trust, says: “In the [past decade], most men being prescribed testosterone would have had organic hypogonadism, whereas in the later years a greater proportion would be receiving it for vague symptoms relating to obesity and sexual dysfunction.

“It would be very useful to know whether venous thromboembolism risk was lower in the first half of the decade they studied compared to the second.”

In June 2014, regulators in Canada and the United States added general warnings in the drug labelling of all approved testosterone products about the risk of venous thromboembolism, but the evidence has been mixed with studies.

The researchers say that the risk associated with testosterone treatment is comparable to that seen in women taking the combined oral contraceptive pill or oestrogen replacement therapy for menopause.

They say the reason for the increase is not totally clear but it is separate from other increased risks of cardiovascular events in middle aged and older men taking testosterone.

“Future research is needed to confirm this temporal increase in the risk of venous thromboembolism and to investigate the risk in first time testosterone users and confirm the absence of risk with long-term use,” the team concludes.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20202071

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00Buy now
  • Integrated Pharmacy Case Studies

    Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

    £47.00Buy now
  • Remington Education: Drug Information and Literature Evaluation

    Remington Education: Drug Information and Literature Evaluation

    Remington Education: Drug Information & Literature Evaluation teaches students how to effectively and efficiently locate and analyze up-to-date drug information and literature.

    £27.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Pharmacy OSCEs

    Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Blood clot micrograph

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.